JP2024073470A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024073470A5 JP2024073470A5 JP2024026729A JP2024026729A JP2024073470A5 JP 2024073470 A5 JP2024073470 A5 JP 2024073470A5 JP 2024026729 A JP2024026729 A JP 2024026729A JP 2024026729 A JP2024026729 A JP 2024026729A JP 2024073470 A5 JP2024073470 A5 JP 2024073470A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- soluble
- biologically active
- activity
- radioprotective compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 10
- 230000004223 radioprotective effect Effects 0.000 claims 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 4
- 230000002297 mitogenic effect Effects 0.000 claims 4
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 claims 3
- 108010024636 Glutathione Proteins 0.000 claims 3
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 230000004071 biological effect Effects 0.000 claims 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 3
- 235000018417 cysteine Nutrition 0.000 claims 3
- 229960003180 glutathione Drugs 0.000 claims 3
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims 3
- 229960003987 melatonin Drugs 0.000 claims 3
- 108010062580 Concanavalin A Proteins 0.000 claims 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
- 108010047620 Phytohemagglutinins Proteins 0.000 claims 2
- 108010033737 Pokeweed Mitogens Proteins 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 229960002433 cysteine Drugs 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 229960002885 histidine Drugs 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 230000001885 phytohemagglutinin Effects 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 230000006052 T cell proliferation Effects 0.000 claims 1
- -1 gardikimod Chemical compound 0.000 claims 1
- 229960002751 imiquimod Drugs 0.000 claims 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 1
- 239000003226 mitogen Substances 0.000 claims 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- 238000004659 sterilization and disinfection Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862673671P | 2018-05-18 | 2018-05-18 | |
| US62/673,671 | 2018-05-18 | ||
| PCT/US2019/032885 WO2019222638A1 (en) | 2018-05-18 | 2019-05-17 | Protection of biologically active molecules during radiation sterilization |
| JP2021514951A JP7487184B2 (ja) | 2018-05-18 | 2019-05-17 | 放射線滅菌中の生物学的活性分子の防護 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514951A Division JP7487184B2 (ja) | 2018-05-18 | 2019-05-17 | 放射線滅菌中の生物学的活性分子の防護 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024073470A JP2024073470A (ja) | 2024-05-29 |
| JP2024073470A5 true JP2024073470A5 (enExample) | 2024-09-19 |
Family
ID=66770587
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514951A Active JP7487184B2 (ja) | 2018-05-18 | 2019-05-17 | 放射線滅菌中の生物学的活性分子の防護 |
| JP2024026729A Pending JP2024073470A (ja) | 2018-05-18 | 2024-02-26 | 放射線滅菌中の生物学的活性分子の防護 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514951A Active JP7487184B2 (ja) | 2018-05-18 | 2019-05-17 | 放射線滅菌中の生物学的活性分子の防護 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210260225A1 (enExample) |
| EP (1) | EP3793621A1 (enExample) |
| JP (2) | JP7487184B2 (enExample) |
| KR (2) | KR102774917B1 (enExample) |
| CN (1) | CN112135641A (enExample) |
| AU (2) | AU2019269671B2 (enExample) |
| MX (1) | MX2020012237A (enExample) |
| SG (1) | SG11202009795PA (enExample) |
| WO (1) | WO2019222638A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114621467B (zh) * | 2022-05-17 | 2022-07-29 | 天新福（北京）医疗器材股份有限公司 | 一种无菌自固化胶原蛋白修复凝胶及其制备方法 |
| CN115611978B (zh) * | 2022-11-21 | 2023-03-07 | 成都奇璞生物科技有限公司 | 一种辐照保护剂在制备胶原蛋白产品中的用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2649224B2 (ja) * | 1987-02-25 | 1997-09-03 | 旭メディカル 株式会社 | 体液処理装置の滅菌方法および滅菌された体液処理装置 |
| US6551794B1 (en) * | 1995-11-09 | 2003-04-22 | E. R. Squibb & Sons, Inc. | Stable biotinylated biomolecule composition |
| JP4071283B2 (ja) * | 1996-02-05 | 2008-04-02 | 旭化成クラレメディカル株式会社 | 滅菌保護剤及び滅菌方法 |
| US5730933A (en) * | 1996-04-16 | 1998-03-24 | Depuy Orthopaedics, Inc. | Radiation sterilization of biologically active compounds |
| EP1762251A1 (en) * | 2000-03-23 | 2007-03-14 | Clearant, Inc. | Methods for sterilizing biological materials |
| US20030012687A1 (en) | 2000-03-23 | 2003-01-16 | Macphee Martin J. | Methods of sterilizing biological materials |
| US20040086420A1 (en) | 2000-03-23 | 2004-05-06 | Macphee Martin J. | Methods for sterilizing serum or plasma |
| US6682695B2 (en) * | 2001-03-23 | 2004-01-27 | Clearant, Inc. | Methods for sterilizing biological materials by multiple rates |
| US6696060B2 (en) * | 2001-06-14 | 2004-02-24 | Clearant, Inc. | Methods for sterilizing preparations of monoclonal immunoglobulins |
| US6946098B2 (en) | 2001-08-10 | 2005-09-20 | Clearant, Inc. | Methods for sterilizing biological materials |
| US20030031584A1 (en) | 2001-08-10 | 2003-02-13 | Wilson Burgess | Methods for sterilizing biological materials using dipeptide stabilizers |
| US7252799B2 (en) * | 2001-08-31 | 2007-08-07 | Clearant, Inc. | Methods for sterilizing preparations containing albumin |
| US6749851B2 (en) * | 2001-08-31 | 2004-06-15 | Clearant, Inc. | Methods for sterilizing preparations of digestive enzymes |
| EP1415669A1 (en) * | 2002-09-19 | 2004-05-06 | Aventis Behring GmbH | Process for sterilization of protein containing biological compositions |
| US20050069453A1 (en) | 2003-09-29 | 2005-03-31 | Ren-Yo Forng | Methods for sterilizing preparations of urokinase |
| US20050175630A1 (en) * | 2003-12-23 | 2005-08-11 | Eyal Raz | Immunogenic compositions and methods of use thereof |
| GB0626021D0 (en) * | 2006-12-29 | 2007-02-07 | Insense Ltd | The stabilisation of proteins |
| US8304439B1 (en) * | 2007-10-12 | 2012-11-06 | Politechnika Lodzka | Use of quaternary pyridinium salts as a therapeutic or preventing agent against ionizing radiation-induced damage |
| EP2236520A1 (en) * | 2009-03-31 | 2010-10-06 | Leukocare Ag | Stabilizing composition for immobilized biomolecules |
| EP2236617A1 (en) * | 2009-03-31 | 2010-10-06 | Leukocare Ag | Methods of terminal sterilization of biofunctional compositions |
| US8999720B2 (en) * | 2011-11-17 | 2015-04-07 | Medtronic Minimed, Inc. | Aqueous radiation protecting formulations and methods for making and using them |
| CN108064229B (zh) * | 2015-03-12 | 2021-12-28 | 三洋化成工业株式会社 | 蛋白质组合物的制造方法和蛋白质组合物 |
| WO2016146573A1 (en) * | 2015-03-13 | 2016-09-22 | Repoceuticals Aps | Melatonin for preventing and treating radiation cystitis |
| US20160354500A1 (en) * | 2015-06-02 | 2016-12-08 | Medtronic Minimed, Inc. | Protective agents against e-beam irradiation for proteins in optical sensing chemistry |
| CN109640981A (zh) * | 2016-06-29 | 2019-04-16 | 曼隆治疗公司 | 神经激肽-1拮抗剂用于治疗多种瘙痒病症的用途 |
| WO2019166003A1 (zh) * | 2018-03-02 | 2019-09-06 | 郑州大学 | 14-脱氧-11,12-脱氢-8,12-环氧或7,8-烯-穿心莲内酯及其15位取代衍生物和用途 |
-
2019
- 2019-05-17 SG SG11202009795PA patent/SG11202009795PA/en unknown
- 2019-05-17 AU AU2019269671A patent/AU2019269671B2/en active Active
- 2019-05-17 WO PCT/US2019/032885 patent/WO2019222638A1/en not_active Ceased
- 2019-05-17 CN CN201980033117.0A patent/CN112135641A/zh active Pending
- 2019-05-17 MX MX2020012237A patent/MX2020012237A/es unknown
- 2019-05-17 KR KR1020207032785A patent/KR102774917B1/ko active Active
- 2019-05-17 US US17/056,393 patent/US20210260225A1/en active Pending
- 2019-05-17 JP JP2021514951A patent/JP7487184B2/ja active Active
- 2019-05-17 KR KR1020257006233A patent/KR20250030028A/ko active Pending
- 2019-05-17 EP EP19728822.8A patent/EP3793621A1/en active Pending
-
2024
- 2024-02-26 JP JP2024026729A patent/JP2024073470A/ja active Pending
-
2025
- 2025-04-22 AU AU2025202786A patent/AU2025202786A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2492537T3 (es) | Composiciones que comprenden florfenicol o un compuesto relacionado estructuralmente para tratar infección en ganado bovino y porcino | |
| JP5795600B2 (ja) | ベンダムスチンの製剤 | |
| CN102421288B (zh) | 前列环素类似物的固体剂型 | |
| PE20241760A1 (es) | Compuestos antivirales que contienen nitrilo | |
| RU2009141187A (ru) | Серосодержащие соединения как ингибиторы ns3 серинпротеазы вируса гепатита с | |
| HK1045652A1 (zh) | 長期穩定的製劑 | |
| BRPI0414111A (pt) | inibidores heterocìclicos de mek e métodos de uso dos mesmos | |
| CN1484533A (zh) | 联合应用酶抑制剂及其药学组合物治疗和预防动脉硬化、预防和治疗根据杰尔－库姆斯分类法分类的ⅰ型过敏反应以及治疗和预防与毛囊和表皮角化过度和角质细胞的过度增殖相关的皮肤疾病 | |
| BR112017025778A2 (pt) | composto, composição farmacêutica, método de tratar ou melhorar um ou mais sintomas de uma doença proliferativa em um indivíduo, método de inibir o crescimento de uma célula, processo de fabricação, e processo para resolução em um dos enantiômeros do racemato do composto | |
| CA2315262A1 (en) | Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors | |
| CN1175901C (zh) | 一种稳定的干扰素水溶液 | |
| CN110743034B (zh) | 一种内外协同治疗糖尿病溃疡的多功能水凝胶敷料及其制备方法和应用 | |
| JP2008528761A (ja) | 抗菌剤としてのβ−シクロデキストリン誘導体 | |
| AR007021A1 (es) | Derivados de 3-descladinosa-2,3-anhidroeritromicina, procedimientos para su preparacion, compuestos para su exclusivo uso en dichos procedimientosy procedimiento para su preparacion, una composicion farmaceutica para tratar infecciones bacterianas y el uso de estos compuestos para preparar medicamentos | |
| ATE293444T1 (de) | Zusammensetzung und verfahren zur parenteralen anwendung von ibuprofen-d,l-, oder l-lysinat | |
| CN1207271C (zh) | 氨基酸碘络合物 | |
| AR004677A1 (es) | Derivados de la 4-sulfonilbenzoilguanidina o 4-sulfinilbenzoilguanidina, procedimiento para prepararlos y composiciones farmaceuticas que los contienen | |
| US5565558A (en) | Thioretinaco ozonide and enhanced biological activity of thioretinaco ozonide in combination with interferon | |
| AU659997B2 (en) | Stable pharmaceutical compositions containing a fibroblast growth factor | |
| FI100454B (fi) | Hemi-tuotteiden uusi lääkinnällinen käyttö | |
| KR20070037415A (ko) | 산화 안정성 안약 조성물의 제조방법 | |
| RU2020135688A (ru) | Защита биологически активных молекул при радиационной стерилизации | |
| WO2002055661A2 (en) | Fatty acid synthase inhibitors | |
| CN1242812C (zh) | 重组人粒细胞巨噬细胞集落刺激因子（rhGM－CSF）凝胶剂及其生产方法 | |
| WO2008147480A4 (en) | Hydroxamic acid derivatives of 3-phenyl propionic acids useful as thrapeutic agents for treating anthrax poisoning |